Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV515 in Glaucoma and Ocular Hypertension
NCT02371746Phase 2Completed
- Sponsor
- Envisia Therapeutics
- Start
- Jan 2015
- Primary completion
- Feb 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of travoprost in Open-angle glaucoma (OAG), ocular hypertension, sponsored by Envisia Therapeutics. Started Jan 2015; status: completed.
02
Drugs
travoprost
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02371746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371746.